Search Results for "establish"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for establish. Results 231 to 240 of 654 total matches.
Quetiapine for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Dec 19, 1997 (Issue 1016)
or clozapine remains to be established.
THE MEDICAL LETTER (ISSN 1523-2859) is published and printed ...
Quetiapine (Seroquel - Zeneca), a dibenzothiazepine derivative, has been approved by the FDA for treatment of schizophrenia and other psychotic disorders. It is a new addition to the 'atypical' antipsychotics, which include olanzapine (Zyprexa - Medical Letter, 39:5, 1997), risperidone (Risperdal) and clozapine (Clozaril). Atypical antipsychotic drugs generally are less likely to cause extrapyramidal symptoms than older drugs such as haloperidol (Haldol, and others) or the phenothiazines.
Tolcapone for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jun 05, 1998 (Issue 1028)
to levodopa in patients with stable disease. Its long-term safety remains to be established.
THE MEDICAL ...
Tolcapone (Tasmar - Roche), a dihydroxy-methyl-nitrobenophenone, has been marketed as an adjunct to levodopa/carbidopa (Sinemet, and others) for treatment of Parkinson's disease in both stable patients and those with end-of-dose "wearing off"of levodopa.
New Monoclonal Antibodies to Prevent Transplant Rejection
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998 (Issue 1036)
-CD3. It has not been established that they are as effective.
THE MEDICAL LETTER (ISSN 1523-2859 ...
Basiliximab (Simulect - Novartis) and daclizumab (Zenapax - Roche), two mouse/human monoclonal antibodies that block the interleukin-2 (IL-2) receptor on Tlymphocytes, have been approved by the FDA for use in the prevention of acute renal transplant rejection. Both drugs are used with cyclosporine (Sandimmune; Neoral) and corticosteroids. An all-murine anti-CD3 monoclonal antibody, muromonab-CD3 (Orthoclone OKT3), has been available in the USA for many years for treatment of transplant rejection, and has also been used with some success for prophylaxis (MI Wilde and KL Goa, Drugs,...
Thalidomide
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998 (Issue 1038)
is best established in cutaneous manifestations of severe or recurrent ENL, for which
it is considered ...
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications.
Candesartan for Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998 (Issue 1040)
effects remains to
be established. These drugs should be reserved for hypertensive patients who ...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Miglitol for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 21, 1999 (Issue 1053)
than acarbose remains to be established.
THE MEDICAL LETTER (ISSN 1523-2859) is published and printed ...
Miglitol, an oral alpha-glucosidase inhibitor similar to acarbase, is now available for treatment of type 2 diabetes.
Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Jun 26, 2000 (Issue 1081)
has not been established. Increased aminotransferase activity
has also been reported. In animal studies, alosetron ...
Alosetron hydrochloride (Lotronex - Glaxo Welcome), a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is diarrhea.
Cevimeline (Evoxac) For Dry Mouth
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000 (Issue 1084)
other advantage remains to be established.
THE MEDICAL LETTER (ISSN 1523-2859) is published and printed ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Direct-to-consumer Advertisements For Glucophage XR
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001 (Issue 1100)
remains to be established. Patients who are doing well with
immediate-release metformin should probably ...
Full-page newspaper advertisements addressed to patients with type 2 diabetes are promoting the convenience of "NEW once-a-day Glucophage XR (metformin HCl extended-release tablets),"and offering a coupon for a free 30-day supply in the month of March.
Azelaic Acid (Finacea) for Rosacea
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003 (Issue 1165)
the role, if any, that bacteria play in its etiology remains to be established. Metronidazole, the most ...
Azelaic acid 15% gel (Finacea Berlex) is now available in the US for treatment of mild to moderate rosacea. A 20% cream formulation of the drug (Azelex Allergan; Medical Letter 1996; 38:52) has been marketed here since 1996 for treatment of acne. The effectiveness of Finacea compared to its own vehicle and to metronidazole gel is discussed. Information on the drug's mechanism of action, adverse effects, dosage and cost are also included.